Kneevoice Receives FDA 510(k) Clearance for Innovative Cartilage Auscultation System
Santa Monica, CA – February 24, 2026 – Kneevoice, Inc., a medical technology company pioneering objective auscultation technology for musculoskeletal care, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Cartilage Evaluation System. The non-invasive system amplifies and records distinct acoustic vibrations within joints to support objective assessment of cartilage and overall joint condition. The company strategically prioritizing initial commercialization concentrated in the knee joint.
Published Research: Advancing Cartilage Diagnostics
Our innovative approach to diagnosing patellofemoral cartilage damage has been recognized in the Journal of Orthopedic Research.